Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2026-02-22 @ 6:43 PM
Study NCT ID:
NCT03915951
Status:
COMPLETED
Last Update Posted:
2025-11-17
First Post:
2019-04-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Sponsor:
Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-small Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | lung cancer | View |
| None | cancer | View |
| None | non-small cell lung cancer | View |
| None | non small cell lung cancer | View |
| None | NSCLC | View |
| None | Encorafenib | View |
| None | Binimetinib | View |
| None | Phase 2 | View |
| None | Open Label | View |
| None | BRAF mutation | View |
| None | BRAF V600E | View |
| None | Array | View |
| None | Stage IV NSCLC | View |
| None | Metastatic NSCLC | View |
| None | PDL1 | View |
| None | PD-LI | View |
| None | Immunotherapy | View |
| None | First line platinum based chemotherapy | View |
| None | BRAF inhibitor | View |
| None | V600 | View |